Recent Updates
Recently added Catalysts
TLX Positive Sentiment

Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses

Key Takeaway: Telix has successfully produced its first GMP-grade commercial radiopharmaceutical doses at its TMS facility in Belgium. This development marks a significant milestone in expanding access to high-quality radiopharmaceuticals for cancer patients in the region. The facility is equipped with advanced production capabilities, positioning it as a key player in the European market.
Price reaction · baseline $16.41 (2025-06-24 close) · hit pre-market · clean, no other TLX news in the window
day 0 close
-2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • First GMP-grade commercial doses produced in Belgium.
  • Expansion of access to radiopharmaceuticals for cancer patients.
  • Strong leadership and investment in innovative products by Telix.
  • TMS Brussels South enhances production capabilities for future isotopes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease

Full Press Release Details

Melbourne (Australia) and Indianapolis (U.S.) | 25 June 2025
Telix today announces that its Telix Manufacturing Solutions (TMS) facility in Brussels South (Seneffe), Belgium, has produced its first Good Manufacturing Practice (GMP)-grade commercial radiopharmaceutical doses and delivered them to the AIRC [1] hospital collaboration in Charleroi, Belgium.
TMS Brussels South is one of Europe’s largest radiopharmaceutical production facilities, with nine GMP lines, clean rooms, a radiopharmacy, and two cyclotrons across a 2,800 square metre footprint.
Raphael Ortiz, Chief Executive Officer, Telix International, commented, “We are excited to launch Telix’s commercial radiopharmacy capability in Europe and demonstrate our ability to meet the needs of patients and partners. Through our bench-to-bedside capabilities we can now provide GMP-grade products and radiolabelling services to customers in Europe and beyond. This is a further point of differentiation for Telix.”
Dr. Ivan Duran Derijckere, AIRC, added, “Following the accreditation of TMS Brussels South, many more regions in Belgium will now have access to GMP-grade radiopharmaceuticals. I would like to thank Telix for its leadership and continued investment in innovative products and services for patients with cancer, which will have a direct positive impact on outcomes including quality of life.”
Prof. Dr. Nadia Withofs, President of the Belgian Society of Nuclear Medicine (BELNUC) continued, “Belgium and the Wallonia region have a rich history in nuclear medicine, and we are thrilled to see this continue with Telix’s pioneering facility in Brussels South becoming GMP operational. TMS Brussels South can now manufacture GMP-grade ‘hot doses’ that are ready for patients today. And beyond this, the impressive research, development and manufacturing scale-up capabilities mean that it will also serve as a vital hub for future production of clinically and commercially important isotopes and radiopharmaceuticals.”
For more information or to order finished radiopharmaceuticals, active pharmaceutical ingredients, or related services, licensed healthcare professionals in Europe can visit: https://www.radiopharmastore.com/
[1] L’Association Interhospitalière de la Région de Charleroi, an inter-hospital collaboration between three hospitals: Grand Hopital de Charleroi (GHdC), Clinique Notre-Dame de Grâce de Gosselies (CNDG) and HUmani.

Frequently Asked Questions

What are GMP-grade radiopharmaceuticals?

GMP-grade radiopharmaceuticals are produced under Good Manufacturing Practice standards, ensuring quality and safety for patients.

Where is Telix's manufacturing facility located?

Telix's manufacturing facility is located in Seneffe, Belgium.

Who benefits from Telix's new production capabilities?

Patients with cancer in Belgium will benefit from increased access to GMP-grade radiopharmaceuticals.

What is the significance of TMS Brussels South?

TMS Brussels South is one of Europe's largest facilities for producing radiopharmaceuticals, enhancing regional healthcare.

Last updated: Jun 25, 2025